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MethotrexateAbstract Introduction: Behc¸et’s disease (BD) is a multisystem disorder that may be associated
with systemic vasculitis, uveitis, retinal vasculitis, and optic neuropathy.
Aim of this work: To evaluate the efﬁcacy of intravitreal methotrexate (MTX) for the treatment
of ocular posterior segment involvement in BD patients.
Patients and methods: Twenty adult Behcet’s disease patients suffering from BD-associated ocu-
lar inﬂammation with posterior segment involvement were included in the present study. Disease
activity was assessed using the Behcet’s Disease Current Activity Form (BDCAF) score. All patients
underwent complete ophthalmologic examination, which included the best corrected visual acuity
testing (VA), slit-lamp biomicroscopy, tonometry, and indirect ophthalmoscopy. Injection of
400 lg/0.1 ml of MTX intravitreally was done once monthly for 3 months.
Results: Visual acuity (initially 2.8 ± 2.03) signiﬁcantly improved in 16 eyes (80%) at the
3- (4.3 ± 2.3) and 6-month (4.1 ± 1.3) (p= 0.02) follow-up examinations. During 6 months of
follow up period after methotrexate treatment, the mean dose of corticosteroids decreased in all
patients and two of nine patients receiving azathioprine were able to decrease the dose. Four eyes
showed a galloping cataract following the injection with worsening of VA despite the improvement
in posterior segment involvement as detected by ultrasonographic examination. Five eyes (25%)
relapsed and the mean number of relapses decreased signiﬁcantly after MTX injection (p= 0.01).
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BD patients with posterior segment involvement, and may allow the reduction of corticosteroids
and immunosuppressive drugs.
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Behc¸et’s disease (BD) is an idiopathic, chronic, inﬂammatory
disorder that was ﬁrst described in 1937 as a triad of symptoms
consisting of oral aphthae, genital ulcers, and hypopyon iritis
[1]. Diagnostic criteria of BD are recurrent oral aphthous
ulcers plus two of the following: recurrent genital ulcers, ocular
inﬂammation, skin involvement, and positive pathergy test
results [2].
Ocular involvement usually occurs within two years of the
onset of the disease and may occur in up to 70% of the BD
patients, in the form of anterior uveitis, retinal vasculitis (both
veins and arteries), optic neuropathy, retinal inﬁltrates, scleri-
tis, and vitritis [3]. Uveitis is deﬁned as an inﬂammatory pro-
cess affecting the iris, ciliary body, or choroid layer of the
eye. Anterior uveitis implies inﬂammation in the iris or ante-
rior ciliary body. Intermediate uveitis describes inﬂammation
in the posterior ciliary body and associated retina, and inﬂam-
mation in the choroid is described as posterior uveitis [4]. Pos-
terior segment involvement usually occurs in the form of
retinitis. Unless diagnosed early and treated properly, retinal
vasculitis in Behc¸et’s disease may cause severe visual loss [5].
Loss of vision due to intraocular inﬂammation can occur
through many mechanisms including retinal inﬂammation,
optic nerve inﬂammation and macular edema. In response to
inﬂammation within the macula, accumulation of ﬂuid occurs
within the loosely woven ﬁbers of Henle in the outer plexiform
layer which is called cystoid macular edema, a common reason
for vision loss with uveitis [4].
Anti-inﬂammatories, speciﬁcally corticosteroids, are very
effective in the treatment of uveitis and associated macular
edema. Though the disease may initially respond to treat-
ment with systemic corticosteroids, it will invariably become
resistant and may need additional treatments [6]. Behc¸et’s
uveitis is one of the absolute indications of immunomodula-
tory therapy. The use of immunosuppressive drugs has gen-
erally resulted in an arrest of the disease process and
induced a long term remission [7]. Methotrexate, is an anti-
metabolite that was introduced for the treatment of rheuma-
toid arthritis (RA) [8]. Intravitreal methotrexate was used
for the treatment of recurrent intraocular lymphoma. It pro-
longed local remission of ocular disease even with an aggres-
sively growing tumor [9].
The aim of this work was to evaluate the efﬁcacy of intra-
vitreal methotrexate injection for the treatment of posterior
segment involvement in Behc¸et’s disease.
2. Patients and methods
The present work was a prospective, interventional, consecu-
tive case series study. It was conducted in the period between
March 2011 and September 2013.Study population: This study was performed on 20 Behc¸et’s
disease patients with posterior segment involvement. They
were 16 males and 4 females attending the Rheumatology
and Rehabilitation Department and Ophthalmology Depart-
ment, Faculty of Medicine, Cairo University. The diagnosis
of Behc¸et’s disease was based on satisfying the set of diagnostic
criteria published by the International Study Group for
Behc¸et’s disease in1990 [2].
Full history taking, clinical examination, and skin pathergy
test were carried out for all patients. Patients were retrospec-
tively reviewed to obtain a standard data set which included:
patient’s demographic characteristics; disease manifestations,
disease duration, and previous immunosuppressant therapy.
Current medications received by the patients were considered
and patients receiving corticosteroids for the management of
their disease were not excluded. Disease activity was assessed
using the Behcet’s Disease Current Activity Form (BDCAF)
score [10]. The self rating scale was not done for simplicity.
Also, routine laboratory investigations were done to all
patients for the measurement of levels of fasting blood sugar,
urea, creatinine, serum uric acid, serum aspartate transaminase
(AST), serum alanine transaminase (ALT), serum albumin,
complete blood count, and erythrocyte sedimentation rate.
Ophthalmological examination: Each patient was subjected
to complete ophthalmologic examination, which included cor-
rected visual acuity (VA) testing, slit-lamp biomicroscopy,
tonometry, and indirect ophthalmoscopy. Other investigations
including fundus photography, ﬂuorescein angiography, and
ultrasonography were performed as indicated.
Inclusion criteria: All patients had severe unilateral active
posterior segment intraocular inﬂammation, active posterior
uveitis despite of other immunosuppressive treatment. Activity
of disease was deﬁned as cells and ﬂare in the anterior cham-
ber, vitreous cells, retinal perivascular sheathing, retinal inﬁl-
tration, new retinal hemorrhages, or optic papillitis [11]. A
relapse was deﬁned as ﬂare-up of activity of disease occurring
three or more months after a period of inactivity. Remission
was deﬁned as P3 months of inactive disease without treat-
ment [12].
Exposure: Each patient was told the steps of the procedure
and gave written informed consent. The study protocol was
approved by our local ethics committee. Injection was per-
formed, together with full asepsis, preoperative cleaning of
the conjunctival sac with povidone-iodine 5%, and topical
anesthesia with topical benoxinate HCl 0.4% drops. Then
400 lg/0.1 ml of MTX was intravitreally injected via the pars
plana, 3.5 to 4.0 mm posterior to the inferotemporal limbus,
with a 27-gauge needle. Intravitreal methotrexate injections
(400 lg/0.1 ml were performed once monthly for 3 months.
Follow up: Patients were examined one week post-injection
and monthly thereafter for a period of 6 months. At each visit,
measurement of the visual acuity (VA) using a Snellen chart
(on a scale of 10), and intraocular pressure (IOP) was made,
Table 1 Demographic data, clinical manifestations and lab-
oratory investigations of Behc¸et’s disease patients.
Demographic data Mean ± SD Range
Age (years) 39.4 ± 4.1 31.4–49.2
Disease duration (years) 7.6 ± 1.02 2–10.8
Clinical manifestations N= 20 %
Recurrent Oral ulcers 20 100
Buccal 16 80
Gingival 1 5
Lip 4 20
Tongue 4 20
Genital ulcers 7 35
Genital scars 3 15
Eye involvement 20 100
Anterior uveitis 4 20
Posterior uveitis 20 100
Cells in the vitreous ﬂuid 16 80
Retinal vasculitis 20 100
Skin involvement 13 65
Erythema nodosum 2 10
Pseudo folliculitis 4 20
Papulopustular lesions 7 35
Acneiform nodules 2 10
Positive Pathergy test 9 45
Fatigue 18 90
Peripheral vascular involvement 5 25
Deep venous thrombosis 1 5
Superﬁcial thrombophlebitis 4 20
Joint involvement 12 60
Arthralgia 12 60
Arthritis 1 5
Neurological aﬀection 4 20
Headache 3 15
Syncopal attacks 1 5
Laboratory investigations Mean ± SD Range
Hemoglobin (gm/dl) 10.8 ± 2.01 8.1–12.4
Erythrocyte sedimentation
rate (1st hour)
60.4 ± 10.2 50.3–71.1
Table 2 Current medications received by Behc¸et’s disease
patients.
Medications (dose) N= 20 % Mean ± SD
Corticosteroids 20 100 23.2 ± 2.1
Colchicine 15 75 1.3 ± 0.7
Azathioprine 9 45 105.6 ± 30.1
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within the vitreous cavity, and dilated fundoscopy to see cellu-
lar inﬁltrates involving the retina. Gonioscopic examination
was added to the monitoring protocol to identify iris and ante-
rior chamber angle neovascularization.
Exclusion criteria: included pregnancy, breast feeding,
impaired liver functions, concurrent active infection, and
end-stage disease with no light perception attributable to
retinal ischemia or optic atrophy, or bilateral irreversible
blindness. Contraceptive advice was given to women and
men with partners of childbearing age.
Statistical analysis: Data were coded and entered using the
statistical package SPSS version 15 for windows. Data were
summarized using mean ± SD for quantitative variables and
frequency and percentage for qualitative variables. Signiﬁcant
differences were calculated using student’s t-test and
Mann–Whitney U test for continuous variables. For compar-
ing categorical data, chi square (v2) test with Yates’ correction
or Fisher’s exact tests were used. P value < 0.05 was consid-
ered signiﬁcant.
3. Results
This study included 20 adult patients with BD (16 males and 4
females), the mean age of the patients was 39.4 ± 4.1 years,
and the mean disease duration was 7.6 ± 1.02 years.
Demographic, clinical manifestations and laboratory inves-
tigations of BD patients are shown in Table 1. Serum levels of
fasting blood sugar, urea, creatinine, serum uric acid, serum
aspartate transaminase (AST), serum alanine transaminase
(ALT), serum albumin and complete blood count, were within
normal ranges. The BDCAF score of the patients ranged from
2 to 6 with a mean of 5.1 ± 0.5. Current medications received
by patients in this study are presented in Table 2.
Effect of intravitreal MTX on visual acuity (VA) and
number of relapses: VA improved after intravitreal MTX in
16 eyes (80%). Improvement in Behc¸et’s disease associated
severe posterior uveitis after intravitreal MTX injection is
shown in Fig. 1.
There was a statistically signiﬁcant difference in VA at the
3- and 6-month follow-up examinations. Mean VA was
2.8 ± 2.03 before MTX treatment and improved after
3 months to 4.3 ± 2.3, then to 4.1 ± 1.3 (p= 0.02).
Five eyes (25%) relapsed and the mean number of relapses
of uveitis decreased signiﬁcantly after MTX injection
(p= 0.012), as shown in Table 3 and Fig. 2.
Ability to taper steroids and other immunosuppressive drugs:
The mean dose of corticosteroids decreased in all patients after
methotrexate treatment, although the difference was statisti-
cally insigniﬁcant (p= 0.099). After methotrexate treatment,
2 patients of 9 (22%) were able to decrease the dose of
azathioprine.
Tolerance and side effects: Four eyes (20%) showed a gal-
loping cataract following the injection with worsening VA
despite the improvement in posterior segment involvement as
detected by ultrasonographic examination.
4. Discussion
Targeting the speciﬁc cellular components involved in the
pathogenesis of tissue destruction ensures a successful
immunotherapy of intraocular diseases. Activated CD4+ Tcells demonstrated in the retinal perivascular inﬁltrates and
within the retinal vessel walls in patients with Behc¸et’s uveitis
[13], suggested that Behc¸et’s uveitis may be a T cell-mediated
autoimmune disease, yet, the immunopathogenic mechanisms
are unclear [14]. The enhanced inﬂammatory reaction in BD
appears to be mediated by cytokines derived from T helper
type I lymphocytes, including IL-2, Interferon gamma (INF)
and tumor necrosis factor (TNF)-alpha [15]. These demonstra-
tions suggest future treatment directed toward down
regulation of the effects of CD4+ T cells that would be
Figure 1 Behc¸et’s disease associated severe posterior uveitis and vitreal haze (a), marked improvement after intravitreal methotrexate
injection (b).
Table 3 Visual acuity, number of relapses and dose of steroids
before and after methotrexate injection in Behc¸et’s disease
patients.
Parameter (mean ± SD) Before MTX After MTX p Value
Visual acuity 2.8 ± 2.03 4.1 ± 1.3 0.02
Number of relapses 2.15 ± 0.99 1.25 ± 1.16 0.012
Dose of steroids (mg) 23.2 ± 2.1 22.1 ± 2.01 0.099
MTX=methotrexate.
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has anti-inﬂammatory and antiproliferative (immunosuppres-
sive) actions: (i) inhibition of thymidylate synthetase resulting
in decreased pyrimidine synthesis, (ii) inhibition of dihydrofo-
late reductase results in inhibition of transmethylation reac-
tions essential for cellular functioning and (iii) Inhibition of
aminoimidazole carboxamide ribonucleotide (AICAR)
transformylase/IMP cyclohydrolase (ATIC) resulting in
increased intracellular and extracellular adenosine which is a
potent inhibitor of inﬂammation that induces vasodilatation,Figure 2 Mean visual acuity in Behc¸et’s disease paand modulates cell trafﬁcking [16]. Adenosine also suppresses
the proinﬂammatory mediators TNF-a, IL-6, IL-8, macro-
phage inﬂammatory protein–1a, leukotriene B4, and nitric
oxide, and enhances the production of the anti-inﬂammatory
mediators IL-10 and IL-1 receptor antagonist [17,18]. Ulti-
mately, adenosine leads to the resolution of inﬂammation by
downregulating macrophage activation and promoting a shift
from a T helper type 1 to a T helper type 2 response [16].
Methotrexate has been widely used in ophthalmic diseases,
systemically and locally. It has been used for the treatment of
recurrent intraocular lymphoma [9,19]. It was also used in the
treatment of non infectious ocular inﬂammation: anterior uve-
itis, intermediate uveitis, posterior or panuveitis, scleritis, ocu-
lar mucous membrane pemphigoid [20], as well as advanced
proliferative diabetic retinopathy [21].
Local treatment of ocular inﬂammation via intravitreal
injection is preferred when possible, especially for unilateral
diseases. Intravitreal MTX avoids systemic toxicity, and can
provide consistent therapeutic drug concentrations [22]. Also,
intravitreal MTX is able to maintain therapeutic doses in the
vitreous humor for 5 days [9].tients before and after intravitreal methotrexate.
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MTX in 16 eyes (80%). VA improved signiﬁcantly at the
3- and 6-month follow-up examinations. The mean number
of relapses decreased signiﬁcantly after MTX injection
(p= 0.012). Moreover, patients were able to decrease the dose
of corticosteroids following intravitreal MTX, although the
difference between the mean corticosteroid doses before and
after MTX was statistically insigniﬁcant (p= 0.099). After
methotrexate treatment, two of nine patients were able to
decrease the dose of azathioprine. Regarding the side effects,
four eyes showed a galloping cataract following the injection
with worse VA despite the improvement in posterior segment
involvement as detected by ultrasonographic examination.
Our results support another study by Taylor and associates
[23] that was conducted on 15 patients with unilateral uveitis
and/or cystoid macular edema. They reported improved VA
at all time points that was statistically signiﬁcant at the
3- and 6-month follow-up examinations. There was a non
signiﬁcant statistical difference between the best VA obtained
after MTX injection and after previous corticosteroid treat-
ment, including intravitreal triamcinolone acetate injection.
They also reported that, ﬁve patients relapsed after a median
of 4 months. Also, ocular inﬂammation scores improved at
all time points, and systemic immunosuppressive medication
was reduced in 3 of 7 patients taking this at the start of the
trial. One patient developed transient corneal epitheliopathy,
one pseudophakic patient developed dense posterior capsular
opaciﬁcation, and one other pseudophakic recorded drug-
related adverse events [23]. Despite the fact that intravitreal tri-
amcinolone can be also used for ocular inﬂammation and asso-
ciated macular edema; complications can arise including
elevated intraocular pressure, cataract, and rarely infectious
endophthalmitis [4]. In a multicenter, retrospective interven-
tional case series of 30 patients with 38 eyes involved with non-
infectious uveitis, intravitreal MTX effectively improved VA
and reduced cystoid macular edema and in some patients,
allowed the reduction of immunosuppressive therapy. Some
patients relapsed at 3 to 4 months, but the larger proportion
(73%) entered an extended period of remission of up to
18 months [24]. In a study on the effect of intravitreal MTX
in 7 BD patients with unilateral active retinal vasculitis that
failed to respond to conventional treatment, together with a
history of increased intraocular pressure or intolerance to cor-
ticosteroid administration, it was found to be well tolerated,
effectively improved VA and was associated with a signiﬁcant
reduction of the cytokine levels even in steroid responders with
refractory retinal vasculitis [25].
In conclusion, intravitreal MTX can improve VA and
reduce posterior segment manifestations in BD patients with
posterior segment involvement, and may allow the reduction
of corticosteroids and immunosuppressive drugs.
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